N/A N=300 The Effect of Age on the Incidence of Postoperative Residual Neuromuscular Blockade
Residual Neuromuscular Blockade in Elderly Patients
Primary: Incidence of Residual Neuromuscular Blockade — 45; 86 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=32 Neuromuscular Blocking Agents in the Elderly
Elective Surgery
Primary: Onset Time — 135; 90 seconds — p=<0.001
Phase 4 N=302 Residual Curarization and Its Incidence at Tracheal Extubation (P08194)
Observation of Neuromuscular Block
Primary: Percentage of Participants With Residual Neuromuscular Blockade (NMB)(Train of Four [TOF] Ratio <0.9) at Time of Tracheal Extubation — 56 percentage of participants
N/A N=366 Incidence of Postoperative Residual Neuromuscular Blockade in Portugal
Residual Neuromuscular Blockade · Residual Paralysis, Post-Anesthesia · Observational Study
Primary: Percentage of Patients With Postoperative Residual Neuromuscular Blockade — 20 Participants
Phase 4 N=40 Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery
Spine Surgery
Primary: Difference in Time of Neuromuscular Recovery From a Neuromuscular Moderate Blockade — 3.9; 26.29 Minutes
Phase 4 N=50 Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block
Neuromuscular Blockade
Primary: Urine Residual in PACU — 219; 222 ml
Phase 3 N=62 Comparision of Different Dose of Neostigmine at Advanced Decurarization
Anesthesia
Primary: Mesure of the Train-of-four (TOF) — 3.8; 4.5; 11.5; 19 minute
Phase 4 N=163 Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex
Muscle Weakness
Primary: Incidence of Postoperative Residual Neuromuscular Blockade at Time of Arrival to the Post-anesthesia Care Unit. — 5 Participants
Phase 2 N=49 Neuromuscular Blockade in Patients With Severe Renal Impairment
Neuromuscular Blockade · Renal Impairment
Primary: Time Until Complete Reversal of Neuromuscular Blockade — 14.8; 3.5 Minutes
Phase 3 N=1,008 Reevaluation Of Systemic Early Neuromuscular Blockade
Acute Respiratory Distress Syndrome
Primary: Hospital Mortality to Day 90 — 288; 289; 213; 216 Participants — p=0.93
Phase 4 N=100 Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery
Neuromuscular Blockade · Postoperative Complications
Primary: Number of Participants With Postoperative Pulmonary Complications — 8; 8 Participants — p=1.00
Phase 4 N=189 Best Management of Muscle Relaxation- Objective Monitoring
Residual Paralysis, Post Anesthesia
Primary: Incidence of Postoperative Residual Neuromuscular Blockade at Time of Extubation — 0 Participants
Phase 3 N=154 Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)
Surgical Procedures, Elective
Primary: Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio <0.9 at Post Anesthesia Care Unit (PACU) Entry — 0; 33 participants…
Phase 4 N=200 The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications
Postoperative Complications · Neuromuscular Blockade
Primary: Number of Participants With a Postoperative Pulmonary Complication — 33; 40 Participants
Phase 3 N=75 Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex
Diaphragmatic Dysfunction · Muscle Weakness · Muscle Fatigue
Primary: Electric Activity of the Diaphragm (Microvolts) — 3.7; 4.5; 3.2; 2.9 microvolt
N/A N=117 Intraoperative Neuromuscular Blockade and Postoperative Atelectasis
Thoracic Surgery · One-lung Ventilation
Primary: Atelectasis Area on Chest CT — 1.32; 1.41 percentage of atelectasis volume
Phase 4 N=102 Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures
Laryngoscopic Surgical Procedures
Primary: Proportion of Patients Who Have a Clinically Acceptable Surgical Conditions — 0.89; 1 Proportion of patients
Phase 4 N=70 Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
Neuromuscular Block
Primary: BIS Signal Variability Using the Measured Standard Deviation During the Maintenance Phase of Anesthesia — 7.6; 7.8 units on a scale — p=0.651
Phase 4 N=350 Deep Neuromuscular Block for Laparoscopic Surgery
Laparoscopy · Anesthesia Recovery Period
Primary: Percentage of Patients Recovered Cognitively at 1 Week — 91.8; 92.9 percentage of patients recovered
Phase 4 N=260 Sugammadex vs Placebo to Prevent Residual Neuromuscular Block
General Surgery
Primary: Decreased Minute Ventilation (MV) — 20; 26 Participants
Phase 4 N=61 Effects of Deep Neuromuscular Blockade on Intraoperative Respiratory Mechanics
Laparoscopic Renal Surgery · Laparoscopy · Muscle Relaxation
Primary: Thoracopulmonary Compliance — 51.9; 52.3; 34.6; 31.9 ml/cmH2O
N/A N=30,430 Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
Neuromuscular Blockade
Primary: Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA)…
Phase 4 N=235 Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
Urinary Retention Postoperative · Laparoscopic Cholecystectomy · Neuromuscular Blockade
Primary: Number of Participants With Postoperative Urinary Retention (POUR) of Sugammadex and Neostigmine Groups — 20; 6 Participants
Phase 4 N=81 Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block
Airway Reflexes, Protective · Recovery After Neuromuscular Block · Anesthetic Recovery
Primary: Recovery of Ability to Swallow After Neostigmine/Glycopyrrolate Antagonism of Rocuronium Paralysis. — 16; 25; 10; 6 participants — p=0.11
Phase 4 N=128 The Laparotomy Study
Gastrointestinal Cancer
Primary: Surgical Rating Score — 4; 4.75 units on a scale — p=<0.05
Phase 4 N=46 Sugammadex as Rescue Therapy
Neuromuscular Blockade
Primary: The Time Taken to Achieve a TOF Ratio of 0.9 After Administration Sugammadex — 3.13; 2.56; 2.33; 5.00 minutes
Phase 4 N=116 Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?
Arthropathy of Hip
Primary: Surgical Conditions — 1; 2; 11; 10 Participants
Phase 4 N=108 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer
Neuromuscular Blockade
Primary: Number of Participants Attaining a 5 (Optimal) Surgical Condition Score — 16; 38 Participants
Phase 3 N=100 Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)
Anesthesia
Primary: Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation — 1.02; 0.78 T4/T1 Ratio
Phase 4 N=100 Neuromuscular Blockade on Shoulder Pain of Elderly
Malignant Neoplasms of Digestive Organs · Malignant Neoplasms of Female Genital Organs · Malignant Neoplasms of Male Genital Organs
Primary: Percentage of Patients Who Reported Shoulder Pain — 12; 10 percentage of participants